109 results
6-K
EX-99.1
GLPG
Galapagos NV
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
, CEO Onno van de Stolpe will maintain oversight of the research and development activities, while Bart Filius will take responsibility for business … Officer and subsequently took on the responsibility as COO in 2017. During these years, Bart managed the substantial growth of the company, successfully
6-K
EX-99.1
GLPG
Galapagos NV
15 Dec 20
Current report (foreign)
4:55pm
Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting --
-- Galapagos to Assume Sole Responsibility … --
-- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials --
-- Gilead will Pay Galapagos €160 million to Support Ongoing Development
6-K
EX-99.1
GLPG
Galapagos NV
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
enrolled into the phase 3 study across 369 global sites
Topline data anticipated in H1 2023
Galapagos will assume responsibility for the DIVERSITY study … for CD is investigational and is not approved anywhere globally.
Galapagos will assume operational and financial responsibility for DIVERSITY
6-K
EX-99.1
GLPG
Galapagos NV
9 Apr 21
Extension of lock-up period in Gilead-Galapagos collaboration agreement
6:00am
(IBD). Gilead will retain operational responsibility for the current trials in Crohn’s disease while Galapagos will assume operational responsibility
6-K
EX-99.2
GLPG
Galapagos NV
11 Apr 22
Current report (foreign)
5:14pm
of Companies and Associations. The new board of directors will be the ultimate decision-making body and will have the overall responsibility … to appoint a lead non-executive director if and as long as the CEO serves as chair. The role and responsibility of the lead non-executive director
6-K
hsrj8uk15ozqtzxc6o
28 Apr 22
Current report (foreign)
4:06pm
6-K
EX-99.1
8zri oluu30kgcn
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
xf998f
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.8
al05pqr5ef0e g174
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.5
6ibfg9f
1 Apr 19
Current report (foreign)
12:00am
6-K
EX-99.3
j0wx itu8dlvz2wt
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.1
h1mdwll0ku5hxww9 fr
23 Jun 21
Galapagos announces departure of CSO Piet Wigerinck later this year
6:00am
6-K
EX-99.7
2hhkqd9i
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.4
qxsvhmn7omh i0a4q
25 Mar 21
Publication of the annual report and invitation to the The annual report for the financial year 2020, including a review of figures and performance, is available online at
12:00am
6-K
EX-99.1
32jvlf4
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.5
pc0sof8jrgkkupq094k
27 Mar 20
Publication of the annual report and invitation to the The annual report for the financial year 2019, including a review of figures and performance, is available online at
4:49pm
6-K
EX-99.1
iqrcc9rouhx3etw4
20 Sep 21
Current report (foreign)
9:26am
6-K
EX-99.4
820742fms36uukjmxz
20 Sep 19
Current report (foreign)
4:07pm
6-K
EX-99.1
8rdmtohb vrrrma4
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
6-K
EX-99.1
ck3a kygo
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am